DNA X delays Q2 10-Q filing, cites convertible debt and consolidation accounting complexities
SONM•Preliminary operating result
- DNA X said net loss from continuing operations is expected near $1 million, versus about $1.9 million a year earlier.
Accounting issues cited in the delay
- The filing delay is tied to accounting for the sale of convertible debt, variable interest entities under ASC 810, and the consolidation of DNA X, LLC.
- A put option termination on May 27, 2026 triggered a conclusion that DNA X, LLC is fully controlled, requiring GAAP consolidation.
Quarterly filing delayed for June 30 period
- DNA X filed a Form 12b-25 to delay its quarterly report for the period ended June 30, 2026.
- The quarterly report is expected on or before the fifth calendar day after the original due date.
Related News
Cirrus expands Grand Forks manufacturing plant by 30,000 square feet to boost capacity
XLI•
Retractable Technologies Q2 FY26 operating loss unchanged at $5.1 million; domestic revenue drops 30.8% on-year
RVP•
